In addition, Hu et al88 demonstrated that CYT387 was highly effective in combination with EGFR inhibitor against NSCLC tumors, particularly with EGFR inhibitor tumors that have intrinsic resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.